Role of Endogenous Adrenomedullin in the Regulation of Vascular Tone and Ischemic Renal Injury
-
- Hiroaki Nishimatsu
- From the Departments of Urology (H.N., T.K.) and Internal Medicine (Y.H., T.S., H.K., M.K., D.N., H.H., H.S., M.S., A.T., E.S., R.N.), Faculty of Medicine, The University of Tokyo; and the Research Institute (K.K., H.M.), National Center of Cardiovascular Medicine, Japan.
-
- Yasunobu Hirata
- From the Departments of Urology (H.N., T.K.) and Internal Medicine (Y.H., T.S., H.K., M.K., D.N., H.H., H.S., M.S., A.T., E.S., R.N.), Faculty of Medicine, The University of Tokyo; and the Research Institute (K.K., H.M.), National Center of Cardiovascular Medicine, Japan.
-
- Takayuki Shindo
- From the Departments of Urology (H.N., T.K.) and Internal Medicine (Y.H., T.S., H.K., M.K., D.N., H.H., H.S., M.S., A.T., E.S., R.N.), Faculty of Medicine, The University of Tokyo; and the Research Institute (K.K., H.M.), National Center of Cardiovascular Medicine, Japan.
-
- Hiroki Kurihara
- From the Departments of Urology (H.N., T.K.) and Internal Medicine (Y.H., T.S., H.K., M.K., D.N., H.H., H.S., M.S., A.T., E.S., R.N.), Faculty of Medicine, The University of Tokyo; and the Research Institute (K.K., H.M.), National Center of Cardiovascular Medicine, Japan.
-
- Masao Kakoki
- From the Departments of Urology (H.N., T.K.) and Internal Medicine (Y.H., T.S., H.K., M.K., D.N., H.H., H.S., M.S., A.T., E.S., R.N.), Faculty of Medicine, The University of Tokyo; and the Research Institute (K.K., H.M.), National Center of Cardiovascular Medicine, Japan.
-
- Daisuke Nagata
- From the Departments of Urology (H.N., T.K.) and Internal Medicine (Y.H., T.S., H.K., M.K., D.N., H.H., H.S., M.S., A.T., E.S., R.N.), Faculty of Medicine, The University of Tokyo; and the Research Institute (K.K., H.M.), National Center of Cardiovascular Medicine, Japan.
-
- Hiroshi Hayakawa
- From the Departments of Urology (H.N., T.K.) and Internal Medicine (Y.H., T.S., H.K., M.K., D.N., H.H., H.S., M.S., A.T., E.S., R.N.), Faculty of Medicine, The University of Tokyo; and the Research Institute (K.K., H.M.), National Center of Cardiovascular Medicine, Japan.
-
- Hiroshi Satonaka
- From the Departments of Urology (H.N., T.K.) and Internal Medicine (Y.H., T.S., H.K., M.K., D.N., H.H., H.S., M.S., A.T., E.S., R.N.), Faculty of Medicine, The University of Tokyo; and the Research Institute (K.K., H.M.), National Center of Cardiovascular Medicine, Japan.
-
- Masataka Sata
- From the Departments of Urology (H.N., T.K.) and Internal Medicine (Y.H., T.S., H.K., M.K., D.N., H.H., H.S., M.S., A.T., E.S., R.N.), Faculty of Medicine, The University of Tokyo; and the Research Institute (K.K., H.M.), National Center of Cardiovascular Medicine, Japan.
-
- Akihiro Tojo
- From the Departments of Urology (H.N., T.K.) and Internal Medicine (Y.H., T.S., H.K., M.K., D.N., H.H., H.S., M.S., A.T., E.S., R.N.), Faculty of Medicine, The University of Tokyo; and the Research Institute (K.K., H.M.), National Center of Cardiovascular Medicine, Japan.
-
- Etsu Suzuki
- From the Departments of Urology (H.N., T.K.) and Internal Medicine (Y.H., T.S., H.K., M.K., D.N., H.H., H.S., M.S., A.T., E.S., R.N.), Faculty of Medicine, The University of Tokyo; and the Research Institute (K.K., H.M.), National Center of Cardiovascular Medicine, Japan.
-
- Kenji Kangawa
- From the Departments of Urology (H.N., T.K.) and Internal Medicine (Y.H., T.S., H.K., M.K., D.N., H.H., H.S., M.S., A.T., E.S., R.N.), Faculty of Medicine, The University of Tokyo; and the Research Institute (K.K., H.M.), National Center of Cardiovascular Medicine, Japan.
-
- Hisayuki Matsuo
- From the Departments of Urology (H.N., T.K.) and Internal Medicine (Y.H., T.S., H.K., M.K., D.N., H.H., H.S., M.S., A.T., E.S., R.N.), Faculty of Medicine, The University of Tokyo; and the Research Institute (K.K., H.M.), National Center of Cardiovascular Medicine, Japan.
-
- Tadaichi Kitamura
- From the Departments of Urology (H.N., T.K.) and Internal Medicine (Y.H., T.S., H.K., M.K., D.N., H.H., H.S., M.S., A.T., E.S., R.N.), Faculty of Medicine, The University of Tokyo; and the Research Institute (K.K., H.M.), National Center of Cardiovascular Medicine, Japan.
-
- Ryozo Nagai
- From the Departments of Urology (H.N., T.K.) and Internal Medicine (Y.H., T.S., H.K., M.K., D.N., H.H., H.S., M.S., A.T., E.S., R.N.), Faculty of Medicine, The University of Tokyo; and the Research Institute (K.K., H.M.), National Center of Cardiovascular Medicine, Japan.
書誌事項
- タイトル別名
-
- Studies on Transgenic/Knockout Mice of Adrenomedullin Gene
説明
<jats:p> Adrenomedullin (AM) is a potent depressor peptide whose vascular action is suggested to involve nitric oxide (NO) release. To explore the role of endogenous AM in vascular and renal function, we examined the effects of acetylcholine (ACh), AM, and AM receptor antagonists AM(22-52) and CGRP(8-37) on the renal perfusion pressure (RPP) of kidneys isolated from AM transgenic (TG)/heterozygote knockout (KO) mice and wild-type littermates (WT). Furthermore, we evaluated the renal function and histology 24 hours after bilateral renal artery clamp for 45 minutes in TG, KO, and WT mice. Baseline RPP was significantly lower in TG than in KO and WT mice (KO 93.4±4.6, WT 85.8±4.2, TG 72.4±2.4 mm Hg [mean±SE], <jats:italic>P</jats:italic> <0.01). ACh and AM caused a dose-related reduction in RPP, but the degree of vasodilatation was smaller in TG than that in KO and WT (%ΔRPP 10 <jats:sup>−7</jats:sup> mol/L ACh: KO −48.1±3.9%, WT −57.5±5.6%, TG −22.8±4.8%, <jats:italic>P</jats:italic> <0.01), whereas <jats:italic>N</jats:italic> <jats:sup>G</jats:sup> -nitro- <jats:sc>l</jats:sc> -arginine methyl ester (L-NAME) caused greater vasoconstriction in TG (%ΔRPP 10 <jats:sup>−4</jats:sup> mol/L: KO 33.1±3.3%, WT 55.5±7.2%, TG 152.6±21.2%, <jats:italic>P</jats:italic> <0.01). Both AM antagonists increased RPP in TG to a greater extent compared with KO and WT mice (%ΔRPP 10 <jats:sup>−6</jats:sup> mol/L CGRP(8-37): KO 12.8±2.6%, WT 19.4±3.6%, TG 41.8±8.7%, <jats:italic>P</jats:italic> <0.01). In mice with ischemic kidneys, serum levels of urea nitrogen and renal damage scores showed smaller values in TG and greater values in KO mice (urea nitrogen: KO 104±5>WT 98±15>TG 38±7 mg/dL, <jats:italic>P</jats:italic> <0.05 each). Renal NO synthase activity was also greater in TG mice. However, the differences in serum urea nitrogen and renal damage scores among the 3 groups of mice were not observed in mice pretreated with L-NAME. In conclusion, AM antagonists increased renal vascular tone in WT as well as in TG, suggesting that endogenous AM plays a role in the physiological regulation of the vascular tone. AM is likely to protect renal tissues from ischemia/reperfusion injury through its NO releasing activity. </jats:p>
収録刊行物
-
- Circulation Research
-
Circulation Research 90 (6), 657-663, 2002-04-05
Ovid Technologies (Wolters Kluwer Health)